Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (v 2 for trend ¼ 11.3, Po0.001; r 2 ¼ 0.86, Po0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates (P ¼ 0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
Introduction
Combination chemotherapy including cytosin arabinoside and an anthracyclin (or similar) induces complete remission from acute myeloid leukemia (AML) in more than half of the patients reported in clinical studies. [1] [2] [3] The achievement of complete remission (CR) is a prerequisite for long-term survival and cure. Most young patients are considered eligible for remission induction, postremission treatment with or without stem cell transplantation, and second-line therapy at relapse, and the overall cure rate is about 40%. 3, 4 The outcome for elderly patients with AML remains, however, dismal, [5] [6] [7] [8] [9] [10] [11] [12] [13] since fewer patients are eligible for remission induction, the remission rate is lower, and the remission duration shorter. Older patients more often have adverse risk factors, 14, 15 and comorbidities may result in less tolerance for intensive therapy. Patients over 80 years are usually given palliative therapy only. 11, 13 However, for patients between 60 and 80 years, there is a lack of validated guidelines and thus a considerable heterogeneity in the therapeutic attitude between individual clinicians, clinics, as well as geographical regions. 16, 17 Guidelines for management of patients are derived from clinical studies, all of which include selections of patients compatible with inclusion and exclusion criteria, as well as from other mostly uncontrolled. The discrepancy between the study populations and the overall patients in the clinic is greatest among older patients 18 with impaired performance status and comorbidities.
Sweden has had a compulsary registration of all patients with cancer since 1958. The Swedish Adult Acute Leukemia Registry started in 1997, and almost has full coverage of patients with acute leukemia, also in older ages, including documentation at the time of diagnosis on the patient's eligibility for remission induction according to the responsible physician. We could identify major differences in the selection of elderly AML patients for remission induction between the six Swedish health care regions. Already in the first report from the Leukemia Registry, based on patients diagnosed in 1997, 19 the proportion of patients considered for remission induction varied from 49 to 92% between the six health care regions, with populations ranging from 0.9 to 1.9 million people. This difference was confirmed in subsequent reports, 20, 21 and it was noted that the difference in the proportion of patients judged eligible for remission induction between the regions was greatest in the age group of 70-80 years. This information elicited discussion on the optimal use of combination chemotherapy in elderly patients. The access to and quality of health care are equal between the regions, and economy has not influenced the choice of primary therapy. Therefore, this difference is likely to be the consequence of different attitudes towards remission induction among the hematologists in each individual region. We decided to prospectively evaluate whether or not the remission induction rates influence survival in the current analysis including almost all Swedish AML patients diagnosed between 1997 and 2001, with a median follow-up of 4 years.
Patients and methods
The Swedish Cancer Registry is a compulsory dual report system. All pathology specimens indicating malignancy are reported, including the patient identification, by the pathologist to the Regional Oncology Center, and secondly, all patients with newly diagnosed cancer are reported by the clinical doctor responsible for the diagnosis. However, it is known that some patients are reported to have a cancer diagnosis in the Swedish Cause of Death Registry without having been registered in the Cancer Registry. 22 Requests for additional information are sent out by the Regional Oncology Center unless both clinical and pathology reports are available. The Swedish Adult Acute Leukemia Registry was founded by the Swedish Society of Hematology, is supported by the Swedish Board for Health and Welfare, and run in collaboration with the Regional Oncology Centers in each of the six Swedish health care regions, covering populations ranging from 880 000 to 1 900 000 people. Each region contains one or two university hospitals and three to 10 county hospitals treating leukemia, and there is no referral for treatment in between the regions. Reporting of data on forms by the responsible hematologists started on all patients with acute leukemia, de novo or secondary (blastic crisis of chronic myeloid leukemia excluded), diagnosed from 1997. Patients registered with an ICD code for acute leukemia in the Cancer Registry but missing in the Leukemia Registry were referred by the Regional Oncology Center to the responsible clinic until they reported, and thus almost all patients have triple registrations. Date of death for all patients was checked using the Swedish Population Registry and updated in March 2004. Data in the Leukemia Registry was also validated through a manual check-up of random samples on patients from all regions, comparing data sets with patient records. 21 For the current analysis, patients diagnosed up to 2001 were evaluated on the initiative of the steering group and in agreement with the ethics committees and the Swedish Society of Hematology.
The initial registration form for the Leukemia Registry includes patient identification, use of diagnostic procedures, including cytochemistry, flow cytometry and cytogenetics, and FAB type. Furthermore, the responsible physician is requested to report if a CR is intended or not; this judgement is based on clinical data, local outlines, and individual experience, especially for the elderly where validated guidelines for treatment are not available, but not on karyotype since cytogenetic reports require several weeks whereas induction therapy is scheduled to start immediately if possible. Subsequent reports on the given therapy were in the current analysis disregarded to achieve a true 'intention-to-treat' analysis. Remission induction therapy always consists of an anthracyclin þ cytosin arabinoside, according to regional protocol and estimated patient status, in general TAD or '3 þ 7', with possible dose reductions for the elderly. Patients in remission subsequently receive consolidation. Chemotherapy used with a palliative intent, such as single drug low dose cytosin arabinoside, hydroxyurea, or thioguanin, is not regarded as remission induction, despite the potential for myelosuppression and achievement of remission.
The current analysis on AML excluded acute promyelocytic leukemia (APL), since APL patients are treated differently, they may be brought into remission without combination chemotherapy, and they have a better overall survival, irrespective of age.
To evaluate possible differences in the health status of older citizens in different parts of Sweden, the overall survival on January 1, 2002 of people that were between 70 and 79 years on January 1, 1997, according to the county of residence, was evaluated from the Swedish Population Registry.
Survival rates at 2 years without censored observations were analyzed using w 2 -tests, and other data were analyzed using the Statistica software (Tulsa, OK, USA).
Results
The Swedish National Cancer Registry contained 1980 adult patients with acute leukemia diagnosed between 1997 and 2001. There were 1672 cases with AML, 71 of these were classified as acute promyelocytic leukemia, 245 cases were acute lymphoblastic leukemia, 63 acute undifferentiated/unclassified leukemia, and 12 had no data on subtype. Overall, 40 cases, including patients treated in pediatric departments, were found in the Cancer Registry only (2%); these patients had a median age of 71 years, that is, the same as that of for patients reported to the Leukemia Registry. The Leukemia Registry thus contained data on 1640/1672 cases of AML (98%). Data on the remaining patients were achieved solely from the Cancer and Population Registries and was limited to age, sex, county of residence, ICD code, date of diagnosis, and date of death. Characteristics of patients with AML excluding APL are found in Table 1 .
AML patients were reported from 71 clinical departments; four of them reported more than 100 patients and three 70-100 patients. Diagnostics on non-APL AML were reported to include cytochemistry in 76%, flow cytometry in 77%, and cytogenetics in 66%; all three diagnostic tools were reported to be used in 54%, that is, in 81% of the patients under 60 years of age, and in 68, 48, and 21% in subsequent decades, respectively.
Overall survival according to age in non-APL AML is depicted in Figure 1 . The median follow-up of surviving patients (n ¼ 238) was 1479 days (quartiles 1116-2012 days). Corresponding figures for surviving patients aged 70-79 years (n ¼ 28) were 1209 days (quartiles 935-1693 days). One young patient emigrated after 1 month, and three others did so after 1-2 years of follow-up.
The primary aim of therapy at the time of diagnosis was recorded in 1569 patients with non-APL AML (98%). A total of 602 (38%) in the primary report were considered not eligible for remission induction, and this information was missing in 32 (2%). Figure 2 shows the proportion of patients considered for remission induction according to age and health care region. Each region had a reasonable stable proportion of remission 
Response and survival of AML (non-APL) patients and controls aged 70-79 years according to health care region
To evaluate if the proportion of patients judged to be eligible for remission induction had an influence on the overall survival for the entire population, we chose to evaluate the age group 70-79 years, due to the observed great difference in remission intention between the regions for this age group (Figure 2 , no data in eight patients, 1.6%). The minimum follow-up was 28 months, and at 2 years 11% were alive, with a range from 6 to 21% in the six regions (Table 1 ). There were no long-term survivors among the nine patients who were registered only in the Cancer Registry. The complete remission rate among those judged to be eligible for remission induction was 48%, with no significant difference between the health care regions (Table 1) 
Kaplan-Meier plots on survival according to region showed similarities in long-term survival between regions with similar remission intention rates. To clarify the presentation, we compiled the regions with high (SG þ N), low (S þ W), and intermediate (SE þ UO) remission intention (RI) rates (Figure 2 ) for the plots in Figures 3 and 4 . Median overall survivals ranged from 3 to 6 months, and 10% died within 1 week from diagnosis and 20% within 1 month.
Wider indications for remission induction would be expected to result in an increased early mortality for patients receiving combination chemotherapy, since more patients with poor prognosis are at risk for toxicity. We analyzed the first part of the survival curves for patients judged eligible for remission induction according to region (Figure 4a) , which however did not show differences in early death rate. However, patients judged to be not eligible for remission induction had poorer survival in regions with the widest indications for combination chemotherapy (w 2 , P ¼ 0.032, Figure 4b ), compatible with the selection procedure.
The log rank analysis is constructed to use information from censored observations, and ranks survival without consideration to the interval between events. Therefore, in a population with a very high early death rate and long follow-up such as this, the impact of long-term survivors is not fully appreciated by the log rank analysis. To permit a focus on the clinically relevant longterm survival we omitted early deaths by performing a landmark survival analysis of all patients 70-79 years old, irrespective of remission intention, who survived at least 1 month, that is, a time point when the survival of patients eligible for remission induction were similar in all regions, as seen in Figure 4a . In this landmark analysis, regions with a high remission intention rate had a better survival (log rank, P ¼ 0.003).
In order to evaluate the influence of other risk factors, the distribution of sex, age, and proportion of secondary leukemia within the age group 70-79 years were analyzed according to region. There was no significant difference between any of the individual regions in these respects, except that there were slightly more males in the S-region than in the SE and SG regions. The survival differences according to region were similar in subgroup analyses of patients of either sex (data not shown), and in both de novo (data not shown) and secondary leukemia (below). It is of interest that the variation between health care regions as regards remission intention rate was greater in one-third of the patients with secondary leukemia (data not shown), and the survival difference more pronounced in this cohort (n ¼ 157, log rank analysis P ¼ 0.02; landmark analysis of patients surviving at least 1 month, log rank P ¼ 0.004).
On January 1, 1997 the Swedish population contained 723 001 people aged 70-79 years, and 581 441 (80.4%) of them were alive 5 years later; the proportions ranged between 79.1% for the N-region to 81.2% for the S-region. The 5-year overall survival of the total Swedish population aged 70-79 years was similar in the six regions, and did not rank similar as regards attitude towards remission induction; in fact, this ranking was the reverse.
Discussion
Remission from AML may be achieved in most patients given intensive combination chemotherapy. 1, 3, 4 However, AML in the elderly still confers a poor prognosis. In addition to the older patient's reduced tolerance to chemotherapy and higher risk for adverse prognostic factors, 15 ,23 a reluctance to prescribe intensive therapy to older people might play a role. Remission induction requires prolonged hospitalization and intensive supportive care, which is costly and cumbersome, and the early death rate in older AML patients participating in therapeutic trials is reported to be 17-54%. 1 Therefore, hematologists do not recommend remission induction for patients over a certain age and comorbidity/disability level, but the cutoff age for individual doctors as well as for regions is a matter of opinion. 17 This report, based on the Swedish Cancer Registry and the Acute Leukemia Registry, which contains 98% of all adult AML patients in the Cancer Registry, with a median age of 71 years, indicates that the attitude towards remission induction in elderly patients influences the final outcome. In geographical regions where more elderly patients were considered for remission induction, the long-term survival of the whole population of AML patients aged 70-79 years was increased. Most long-term survivors were treated in regions where most patients were judged to be eligible for remission induction. The survival of all elderly Swedish citizens did not differ correspondingly between the regions, and the analysis of a complete, and therefore Attitude towards remission induction for AML Patients G Juliusson et al unselected population, rather than a sample, makes it unlikely that the survival difference of elderly AML patients would be explained by an uneven distribution of patients between the regions.
The consequences of active versus palliative treatment of elderly AML patients are important issues, but they are difficult to address in clinical trials, where patient selection is great and mostly uncontrolled due to referral patterns and individual judgements. However, data corresponding to ours were achieved from a small randomized EORTC study published in 1989, where 31 AML patients over 65 years receiving combination chemotherapy had a median survival of 21 weeks as compared to 11 weeks for 29 patients on a 'wait-and-see' strategy. 6 The same question was addressed in the recent large UK MRC AML13 study, but no information was achieved since too few patients were judged to be eligible for randomization between active and palliative treatment.
The Swedish Adult Acute Leukemia Registry includes nearly to all acute leukemia patients in large defined geographical regions during a 5-year period, the minimum follow-up was many times longer than the median survival, and a central population registration was used for validating survival data. Acute leukemia in Sweden is not treated in private hospitals, and the registry also includes patients never reaching hematology clinics. There is no flow of elderly patients between the regions, which would have introduced a selection bias. A skew distribution of prognostic factors is thus not likely; however, the registry currently lacks information on other well-known prognostic factors. Such prognostic factors have not been derived from this age group; in the largest study of chromosomes in AML of 'elderly', 291/2677 patients (11%) were 70 years or older, 15 as compared to the median age of 71 years in our registry on adult AML patients including those who are 16 years or older, but not pediatric patients. For the individual patient, a careful clinical evaluation including cytogenetics is important for the treatment decision, 1, 10, 16, 24 but is still not sufficient to identify all potential long-term survivors.
It is not likely that the observed survival difference in the elderly was due to more effective therapy in some regions, considering the well-established standard therapy for AML, 2 the lack of survival improvement in the study arms of many randomized studies, for example, by the MRC, 3,9 EORTC, 8 CALGB, 25 SWOG, 23 ECOG, 26 and LGMS, 27 and the lack of difference between regions in complete remission rate among patients judged eligible for remission induction.
It has been known since 1998 19 that the six Swedish health care regions have had different remission induction rates for elderly AML patients. There has been no common Swedish care program for elderly AML, but therapeutic principles are discussed during regional clinical policy meetings, and the differences in remission induction rates have remained reasonably stable during the duration of the study (data not shown). [19] [20] [21] The current analyses are thus requested prospective testings of predefined hypotheses, and not the result of retrospective multiple statistical procedures. The observed outcome is thus more likely related to the attitude towards remission induction among the clinical hematologists than to patient selection or to the specific treatment for those who received it.
We chose to focus on the age group 70-79 years, because the differences in remission intention rate between the regions were greater than in younger cohorts, and AML patients over 80 years have a poor outcome irrespective of therapy, and a possible benefit from remission induction would be obscured by early therapy-related and unrelated deaths. 11, 13 Our study, in contrast to other reports, gives data on all AML patients, not only those selected for treatment or fulfilling inclusion and exclusion criteria. It is obvious that if only patients selected by any means for remission induction were reported, the results would be better, but our aim was to describe how a general management influences survival of the whole population of AML patients.
In our study, the short-term survival of elderly patients eligible for remission induction was similar in all regions, despite the highly variable proportion of such patients. Thus no increased early death rate from more frequent use of chemotherapy was found (Figure 4a) , and the improved long-term survival was not counteracted by an increased early death rate in this age cohort. Furthermore, patients not eligible for remission induction had poor prognosis in regions with a high remission intention rate (Figure 4b) , reflecting a successful selection of subsets of patients for palliation only.
Patients in remission from acute leukemia require less supportive care and hospitalization, and have a better quality of life than patients during palliation, and the overall hospitalization time was not different between patients on therapy with remission intention and those on 'wait-and-see' strategies in the EORTC trial. 6 It is therefore likely that remission induction is cost-effective in elderly patients also.
With few exceptions, complete remission is a prerequisite for prolonged survival. The overall remission rate and thus longterm survival is likely to increase if more patients are given the chance to achieve a remission, provided that excessive toxicity could be avoided. As this was the case, we suggest that all AML patients younger than 80 years without specific contraindications should be offered a hematologic evaluation and considered for remission induction.
